Edition:
United States

Genocea Biosciences Inc (GNCA.OQ)

GNCA.OQ on NASDAQ Stock Exchange Global Market

1.00USD
3:59pm EST
Change (% chg)

$-0.00 (-0.50%)
Prev Close
$1.01
Open
$1.01
Day's High
$1.02
Day's Low
$0.99
Volume
104,072
Avg. Vol
168,026
52-wk High
$7.28
52-wk Low
$0.79

Chart for

About

Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one... (more)

Overall

Beta: 1.25
Market Cap(Mil.): $82.89
Shares Outstanding(Mil.): 82.07
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 187.16 16.73
EPS (TTM): -- -- --
ROI: -- -0.71 35.60
ROE: -- -3.52 17.23

BRIEF-Genocea Qtrly Loss Per Share $0.37

* GENOCEA REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

Feb 15 2018

BRIEF-Genocea Biosciences Entered Into Agreement With Oncovir For Manufacture & Supply Of Hiltonol

* GENOCEA BIOSCIENCES SAYS ‍ON JAN 26, CO ENTERED INTO AGREEMENT WITH ONCOVIR FOR MANUFACTURE & SUPPLY OF HILTONOL(REG) (POLY-ICLC)​ - SEC FILING Source text: (http://bit.ly/2npDhjw) Further company coverage:

Jan 31 2018

BRIEF-Bvf Partners Reports A 8.9 Pct Passive Stake In Genocea Biosciences As Of Jan 17

* BVF PARTNERS L.P. REPORTS A 8.9 PERCENT PASSIVE STAKE IN GENOCEA BIOSCIENCES INC AS OF JAN 17 - SEC FILING Source text for Eikon: (http://bit.ly/2BDcCno) Further company coverage:

Jan 29 2018

BRIEF-New Enterprise Associates 16 Reports A 39.7 Pct Stake In Genocea Biosciences As Of Jan 17

* NEW ENTERPRISE ASSOCIATES 16, L.P. REPORTS A 39.7 PERCENT STAKE IN GENOCEA BIOSCIENCES INC AS OF JAN 17 - SEC FILING Source text: (http://bit.ly/2Gm4D1B) Further company coverage:

Jan 26 2018

BRIEF-Genocea Biosciences, Inc. Announces Pricing Of $55 Mln Concurrent Public Offerings

* GENOCEA BIOSCIENCES, INC. ANNOUNCES PRICING OF $55 MILLION CONCURRENT PUBLIC OFFERINGS

Jan 17 2018

BRIEF-Genocea Biosciences Announces Proposed Concurrent Public Offerings Of Common Stock

* GENOCEA BIOSCIENCES, INC. ANNOUNCES PROPOSED CONCURRENT PUBLIC OFFERINGS OF COMMON STOCK AND CLASS A WARRANTS AND SERIES A CONVERTIBLE PREFERRED STOCK AND CLASS A WARRANTS

Jan 16 2018

BRIEF-Genocea Biosciences inc qtrly ‍loss per share $0.59​

* Genocea biosciences - ‍expects existing cash and cash equivalents sufficient to support operating expenses and capital expenditure into middle of 2018​

Nov 02 2017

BRIEF-Genocea announces strategic shift to immuno-oncology and the development of neoantigen cancer vaccines

* Genocea announces strategic shift to immuno-oncology and the development of neoantigen cancer vaccines

Sep 25 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF80.20 -0.26
Pfizer Inc. (PFE.N) $35.76 -0.25
Merck & Co., Inc. (MRK.N) $54.55 -0.43
Sanofi SA (SASY.PA) €64.70 +0.15
AstraZeneca plc (AZN.L) 4,799.50 +77.50
GlaxoSmithKline plc (GSK.L) 1,324.60 -0.40
Vical Incorporated (VICL.OQ) $1.48 -0.01

Earnings vs. Estimates